A Phase 3 interventional study of CHF 5993 200/6/12.5 µg and CHF 1535 200/6 µg in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 244 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 2nd largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 44th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Chiesi Farmaceutici S.p.A. · Sites in Bulgaria
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
Chiesi Farmaceutici S.p.A. · Sites in Argentina, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–75
Chiesi Pharma AB, Nordic · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 24 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,437 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 97 across the 66 interventional studies, 300 across the 15 observational. Of the 69 that completed or were terminated, 13 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
2 of the studies in Asthma by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301736Chiesi Farmaceutici S.p.A.Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | 2027-06-03 |
| NCT06908421Chiesi Pharma AB, NordicEfficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) in patients with uncontrolled asthma under medium doses of inhaled corticosteroid/long-acting β2-adrenergic receptor agonists (ICS/LABA), in patients with uncontrolled asthma who received medium doses of ICS/LABA.
The treatments tested the improvement of the forced expiratory volume in the 1st second (FEV1) and the reduction of moderate and severe asthma exacerbations rate.
This was a phase III, multicentre, randomised, double-blind study, with an open-label arm, active-controlled, 3-arm parallel group study to demonstrate both the superiority of CHF 5993 pMDI 200/6/12.5 μg compared with CHF 1535 pMDI 200/6 μg in terms of change from baseline in pre-dose FEV1 at Week 26 and a reduction of moderate and severe asthma exacerbation rate with CHF 5993 pMDI 200/6/12.5 μg compared to CHF 1535 pMDI 200/6 μg during the entire 52-week treatment period.
The study was performed in patients with uncontrolled asthma on high doses of inhaled corticosteroids (ICS) in combination with long acting β2-agonists LABAs). The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and all other requirements of local laws.
Patients completed the electronic diary (eDiary)/electronic peak flow meter (ePeakflowmeter) twice daily at home from screening to Week 52, recording asthma symptoms, treatment compliance, rescue intake and peak expiratory flow (PEF). The Asthma Control Questionnaire© (ACQ)-7 was completed at all visits from screening to Week 52. The EuroQuality of Life-5-Dimensional-3-Level (EQ-5D-3L™) questionnaire was completed at all visits from randomisation to Week 52. Health economic information was collected during the study. An independent Data Safety Monitoring Board was established for evaluation of the study and impartial safety assurance for patients. An Adjudication Committee was established to evaluate Major Adverse Cardiovascular Events.
Primary objective of the study were:
The secondary endpoints included pooled analyse of 2 pivotal studies; this study (TRIGGER) and study (TRIMARAN). These 2 studies have similar study designs and study population.
CHF 1535 pMDI: fixed-dose combination (FDC) of BDP + FF + GB Dose: BDP 200 μg, FF 6 μg, GB 12.5 μg per actuation, 2 inhalations, BID. Total daily dose: BDP 800 μg, FF 24 μg, GB 50 μg.
BDP: Beclometasone dipropionate FF: Formoterol fumarate GB: Glycopyrronium bromide
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB
Drug: CHF 5993 200/6/12.5 µg
Treatment B: CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF
Drug: CHF 1535 200/6 µg
Treatment C (open-label arm): CHF 1535 200/6 µg: 2 inhalations bid \+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio
Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26
Change from baseline in pre-dose FEV1, analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 26.
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period
Asthma exacerbation intensity: Moderate AND Severe Asthma Exacerbation Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
3_Change From Baseline in Peak(0-3h) FEV1 at Week 26
Peak peak of forced expiratory volume in the first second (FEV1) within 3 hours post-dose. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) and Week 26.
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment
Change from baseline in the average morning PEF (Litre/min), measured by patients at home over the 26-week treatment period (i.e., up to Week 26). PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 26.
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis
Severe asthma exacerbation rate over the 52-Week treatment period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: The entire treatment period; up to Week 52.
6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits
The peak (0-3h) FEV1 at baseline and at all subsequent visits, and the respective changes from baseline are presented by treatment group for all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits
Results show the change from baseline in pre-dose FEV1 at all clinical visits. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52
Results show the percentage of patients classified as FEV1 responders at Week 26 and at Week 52. The FEV1 response was defined as: Change from baseline in pre-dose morning FEV1 ≥ 100 mL. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits
Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose). FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits
ACQ-7 Questionnaire. ACQ-7 allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52
Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and at Week 52.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment
Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
12a_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment
Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks
Number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Number of patients at risk of a SEVERE asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER), over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.
MODERATE asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02
Moderate AND severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Time to first MODERATE OR SEVERE asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period
MODERATE asthma exacerbation rate over the 52-Week treatment period. Asthma exacerbation intensity: Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation
Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
21_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods
Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
21a_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period
Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
22_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods
Change from baseline in the percentage of rescue medication-free days over the 26- and 52-Week treatment periods. Data was collected using an electronic daily diary, from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
22a_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment
Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
23_Change From Baseline in the Average Total Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods
Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
23a_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period
Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
24_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods
Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods
Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
25_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods
Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
25a_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period
A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/ take part in usual activity).
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
Overall, 2100 patients were screened according to inclusion and exclusion criteria; of these,1437 patients were randomised. Overall, 6 patients were randomised in error and did not start treatment (N=2 in the CHF 5993 pMDI 200/6/12.5 μg group, N=3 in the CHF 1535 pMDI 200/6 μg group, and N=1 in CHF 1535 pMDI 200/6 μg + tiotropium 2.5 µg group ). The data set Safety population used for the evaluations represents 1431 patients.
| Milestone | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Started | 573 | 576 | 288 |
| Completed | 534 | 533 | 262 |
| Not completed | 39 | 43 | 26 |
| Withdrew: Withdrawal by subject | 26 | 25 | 20 |
| Withdrew: Adverse event | 3 | 7 | 2 |
| Withdrew: Adverse event - serious, fatal | 1 | 1 | 0 |
| Withdrew: Patient decision | 0 | 1 | 0 |
| Withdrew: Patient moved to another town | 1 | 0 | 0 |
| Withdrew: Safety concern | 0 | 0 | 1 |
| Withdrew: Unblinding code broken | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Pregnancy | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 8 | 1 |
Change from baseline in pre-dose FEV1, analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 | 0.229 (0.196 to 0.263) | 0.157 (0.123 to 0.190) | 0.274 (0.227 to 0.321) |
Asthma exacerbation intensity: Moderate AND Severe Asthma Exacerbation Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;
| events/year | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period | 1.726 (1.543 to 1.932) | 1.963 (1.757 to 2.192) | 1.613 (1.373 to 1.897) |
Peak peak of forced expiratory volume in the first second (FEV1) within 3 hours post-dose. FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 3_Change From Baseline in Peak(0-3h) FEV1 at Week 26 | 0.522 (0.488 to 0.556) | 0.417 (0.383 to 0.451) | 0.555 (0.507 to 0.603) |
Change from baseline in the average morning PEF (Litre/min), measured by patients at home over the 26-week treatment period (i.e., up to Week 26). PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| 4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment | 10.102 (6.717 to 13.487) | 2.297 (-1.091 to 5.684) | 10.286 (5.540 to 15.032) |
Severe asthma exacerbation rate over the 52-Week treatment period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis | 0.239 (0.206 to 0.276) | 0.310 (0.271 to 0.354) |
The peak (0-3h) FEV1 at baseline and at all subsequent visits, and the respective changes from baseline are presented by treatment group for all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value. FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| Week 0 | 0.465 (0.438 to 0.492) | 0.407 (0.380 to 0.434) | 0.467 (0.429 to 0.505) |
| Week 4 | 0.533 (0.501 to 0.564) | 0.439 (0.408 to 0.471) | 0.559 (0.515 to 0.604) |
| Week 12 | 0.528 (0.495 to 0.561) | 0.433 (0.400 to 0.466) | 0.545 (0.499 to 0.591) |
| Week 26 | 0.522 (0.488 to 0.556) | 0.417 (0.383 to 0.451) | 0.555 (0.507 to 0.603) |
| Week 40 | 0.522 (0.488 to 0.556) | 0.414 (0.380 to 0.448) | 0.520 (0.472 to 0.568) |
| Week 52 | 0.501 (0.467 to 0.535) | 0.410 (0.375 to 0.444) | 0.529 (0.481 to 0.578) |
Results show the change from baseline in pre-dose FEV1 at all clinical visits. FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| Week 4 | 0.218 (0.189 to 0.248) | 0.149 (0.119 to 0.179) | 0.254 (0.212 to 0.296) |
| Week 12 | 0.241 (0.210 to 0.272) | 0.162 (0.131 to 0.194) | 0.250 (0.206 to 0.294) |
| Week 26 | 0.229 (0.196 to 0.263) | 0.157 (0.123 to 0.190) | 0.274 (0.227 to 0.321) |
| Week 40 | 0.255 (0.221 to 0.290) | 0.162 (0.128 to 0.196) | 0.250 (0.201 to 0.298) |
| Week 52 | 0.238 (0.205 to 0.272) | 0.152 (0.118 to 0.186) | 0.267 (0.219 to 0.314) |
Results show the percentage of patients classified as FEV1 responders at Week 26 and at Week 52. The FEV1 response was defined as: Change from baseline in pre-dose morning FEV1 ≥ 100 mL. FEV1=Forced expiratory volume in the first second
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Week 26 | 328 | 257 | 174 |
| Week 52 | 326 | 241 | 158 |
Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose). FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| Week 0 | 0.357 (0.333 to 0.382) | 0.309 (0.285 to 0.334) | 0.358 (0.324 to 0.393) |
| Week 4 | 0.443 (0.413 to 0.474) | 0.352 (0.322 to 0.383) | 0.472 (0.429 to 0.515) |
| Week 12 | 0.440 (0.409 to 0.472) | 0.343 (0.312 to 0.375) | 0.454 (0.409 to 0.499) |
| Week 26 | 0.429 (0.396 to 0.462) | 0.331 (0.298 to 0.365) | 0.465 (0.419 to 0.512) |
| Week 40 | 0.438 (0.404 to 0.471) | 0.328 (0.295 to 0.362) | 0.431 (0.383 to 0.478) |
| Week 52 | 0.416 (0.383 to 0.449) | 0.328 (0.294 to 0.361) | 0.442 (0.395 to 0.489) |
ACQ-7 Questionnaire. ACQ-7 allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.
| score on a scale | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| Week 4 | -0.573 (-0.621 to -0.524) | -0.513 (-0.562 to -0.464) | -0.576 (-0.645 to -0.507) |
| Week 12 | -0.699 (-0.752 to -0.646) | -0.608 (-0.661 to -0.555) | -0.704 (-0.779 to -0.630) |
| Week 26 | -0.766 (-0.823 to -0.710) | -0.683 (-0.739 to -0.626) | -0.766 (-0.845 to -0.686) |
| Week 40 | -0.796 (-0.854 to -0.738) | -0.698 (-0.756 to -0.640) | -0.767 (-0.849 to -0.684) |
| Week 52 | -0.842 (-0.902 to -0.783) | -0.713 (-0.773 to -0.653) | -0.772 (-0.857 to -0.688) |
Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and at Week 52.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Week 26 | 350 | 319 | 180 |
| Week 52 | 356 | 332 | 168 |
Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 12_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment | 9.805 (6.159 to 13.450) | 1.563 (-2.087 to 5.214) | 8.055 (2.937 to 13.172) |
Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak Expiratory Flow; is the maximal airflow forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | 8.965 (5.530 to 12.400) | -0.306 (-3.744 to 3.131) | 14.249 (9.428 to 19.071) |
| Weeks 1-52 | 7.956 (4.276 to 11.636) | -1.686 (-5.369 to 1.998) | 11.167 (5.999 to 16.336) |
Number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks | 323 | 364 | 162 |
Number of patients at risk of a SEVERE asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER), over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 209 | 257 |
MODERATE asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02. | 1.515 (1.390 to 1.651) | 1.717 (1.577 to 1.869) |
Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 588 | 663 |
Moderate AND severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02 | 1.788 (1.653 to 1.935) | 2.074 (1.920 to 2.241) |
Time to first MODERATE OR SEVERE asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg |
|---|---|---|
| 18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 660 | 743 |
MODERATE asthma exacerbation rate over the 52-Week treatment period. Asthma exacerbation intensity: Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥ 0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥ 20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid;
| events/year | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period | 1.430 (1.264 to 1.618) | 1.583 (1.401 to 1.788) | 1.366 (1.144 to 1.631) |
Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.
| Participants | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| 20_Number of Patients at Risk of a MODERATE Asthma Exacerbation | 283 | 320 | 150 |
Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
| puffs/day | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | -0.575 (-0.647 to -0.502) | -0.550 (-0.623 to -0.478) | -0.672 (-0.775 to -0.570) |
| Weeks 1-52 | -0.638 (-0.713 to -0.562) | -0.582 (-0.658 to -0.506) | -0.686 (-0.792 to -0.579) |
Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.
| puffs/day | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | -0.409 ± 0.984 | -0.421 ± 1.005 | -0.543 ± 0.966 |
| Visit 3 - Visit 4 Weeks 5-12 | -0.549 ± 1.089 | -0.559 ± 1.191 | -0.654 ± 1.143 |
| Visit 4 - Visit 5 Weeks 13-26 | -0.636 ± 1.178 | -0.608 ± 1.279 | -0.738 ± 1.317 |
| Visit 5 - Visit 6 Weeks 27-40 | -0.680 ± 1.236 | -0.624 ± 1.371 | -0.734 ± 1.357 |
| Visit 6 - Visit 7 Weeks 41-52 | -0.726 ± 1.301 | -0.618 ± 1.350 | -0.706 ± 1.420 |
Change from baseline in the percentage of rescue medication-free days over the 26- and 52-Week treatment periods. Data was collected using an electronic daily diary, from screening to the end of the study.
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | 15.786 (13.674 to 17.898) | 14.570 (12.453 to 16.687) | 18.390 (15.407 to 21.373) |
| Weeks 1-52 | 17.566 (15.343 to 19.788) | 15.457 (13.229 to 17.685) | 19.740 (16.598 to 22.882) |
Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 10.075 ± 25.251 | 11.380 ± 26.740 | 14.435 ± 23.979 |
| Visit 3 - Visit 4 Weeks 5-12 | 14.196 ± 29.971 | 14.668 ± 31.945 | 17.854 ± 30.452 |
| Visit 4 - Visit 5 Weeks 13-26 | 17.297 ± 32.990 | 16.094 ± 34.867 | 21.453 ± 34.148 |
| Visit 5 - Visit 6 Weeks 27-40 | 18.216 ± 35.857 | 16.600 ± 37.352 | 22.261 ± 36.189 |
| Visit 6 - Visit 7 Weeks 41-52 | 19.603 ± 36.129 | 16.942 ± 38.749 | 22.541 ± 37.955 |
Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
| score on a scale | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | -0.186 (-0.211 to -0.160) | -0.175 (-0.201 to -0.149) | -0.194 (-0.231 to -0.158) |
| Weeks 1-52 | -0.208 (-0.236 to -0.180) | -0.191 (-0.219 to -0.163) | -0.207 (-0.246 to -0.167) |
Results show the change from baseline in the average total daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
| score on a scale | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | -0.116 ± 0.288 | -0.121 ± 0.274 | -0.140 ± 0.291 |
| Visit 3 - Visit 4 Weeks 5-12 | -0.174 ± 0.348 | -0.171 ± 0.355 | -0.183 ± 0.351 |
| Visit 4 - Visit 5 Weeks 13-26 | -0.211 ± 0.393 | -0.199 ± 0.407 | -0.218 ± 0.381 |
| Visit 5 - Visit 6 Weeks 27-40 | -0.228 ± 0.433 | -0.210 ± 0.440 | -0.237 ± 0.402 |
| Visit 6 - Visit 7 Weeks 41-52 | -0.240 ± 0.437 | -0.209 ± 0.462 | -0.219 ± 0.441 |
Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | 13.187 (11.150 to 15.224) | 10.358 (8.316 to 12.400) | 10.419 (7.541 to 13.296) |
| Weeks 1-52 | 16.569 (14.298 to 18.840) | 12.790 (10.513 to 15.067) | 12.725 (9.514 to 15.937) |
Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 6.260 ± 19.532 | 5.316 ± 19.154 | 4.921 ± 16.053 |
| Visit 3 - Visit 4 Weeks 5-12 | 11.267 ± 26.792 | 9.319 ± 25.430 | 9.663 ± 24.046 |
| Visit 4 - Visit 5 Weeks 13-26 | 16.053 ± 31.199 | 12.839 ± 30.235 | 12.328 ± 27.339 |
| Visit 5 - Visit 6 Weeks 27-40 | 19.543 ± 34.705 | 14.891 ± 32.355 | 14.663 ± 31.889 |
| Visit 6 - Visit 7 Weeks 41-52 | 20.661 ± 35.949 | 15.737 ± 33.931 | 15.949 ± 33.004 |
Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Weeks 1-26 | 12.469 (10.482 to 14.457) | 9.950 (7.958 to 11.942) | 10.356 (7.548 to 13.164) |
| Weeks 1-52 | 15.601 (13.389 to 17.813) | 12.088 (9.870 to 14.307) | 12.530 (9.401 to 15.658) |
A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/ take part in usual activity).
| percentage of days | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium (Tio) 2.5 µg |
|---|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 6.014 ± 18.918 | 5.348 ± 18.493 | 5.078 ± 15.955 |
| Visit 3 - Visit 4 Weeks 5-12 | 10.666 ± 26.147 | 9.138 ± 24.541 | 9.659 ± 24.071 |
| Visit 4 - Visit 5 Weeks 13-26 | 15.062 ± 30.332 | 12.180 ± 29.133 | 12.214 ± 27.180 |
| Visit 5 - Visit 6 Weeks 27-40 | 18.221 ± 33.557 | 14.035 ± 31.704 | 14.295 ± 31.514 |
| Visit 6 - Visit 7 Weeks 41-52 | 19.383 ± 34.482 | 14.619 ± 33.166 | 15.731 ± 32.685 |
Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion week 52 or study discontinuation.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF 5993 200/6/12.5 µg | 1/571 (0.2%) | 28/571 (4.9%) | 406/571 (71.1%) |
| CHF 1535 200/6 µg | 1/573 (0.2%) | 33/573 (5.8%) | 437/573 (76.3%) |
| CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg | 0/287 (0%) | 15/287 (5.2%) | 207/287 (72.1%) |
| Event | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 11/571 | 11/573 | 6/287 |
| PneumoniaInfections and infestations | 3/571 | 5/573 | 2/287 |
| Cardiac hypertrophyCardiac disorders | 0/571 | 0/573 | 1/287 |
| GastritisGastrointestinal disorders | 0/571 | 0/573 | 1/287 |
| PancreatitisGastrointestinal disorders | 0/571 | 0/573 | 1/287 |
| AppendicitisInfections and infestations | 0/571 | 0/573 | 1/287 |
| Perirectal abscessInfections and infestations | 0/571 | 0/573 | 1/287 |
| Radius fractureInjury, poisoning and procedural complications | 0/571 | 0/573 | 1/287 |
| Back disorderMusculoskeletal and connective tissue disorders | 0/571 | 0/573 | 1/287 |
| GynaecomastiaReproductive system and breast disorders | 0/571 | 0/573 | 1/287 |
| Event | CHF 5993 200/6/12.5 µg | CHF 1535 200/6 µg | CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 320/571 | 361/573 | 159/287 |
| NasopharyngitisInfections and infestations | 46/571 | 63/573 | 34/287 |
| Respiratory tract infection viralRespiratory, thoracic and mediastinal disorders | 17/571 | 28/573 | 14/287 |
| HeadacheNervous system disorders | 25/571 | 27/573 | 13/287 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 18/571 | 18/573 | 12/287 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 8/571 | 15/573 | 7/287 |
| HypertensionVascular disorders | 10/571 | 6/573 | 7/287 |
| Back painMusculoskeletal and connective tissue disorders | 12/571 | 5/573 | 7/287 |
| PharyngitisRespiratory, thoracic and mediastinal disorders | 10/571 | 12/573 | 4/287 |
| RhinitisRespiratory, thoracic and mediastinal disorders | 7/571 | 12/573 | 4/287 |
| Age, Categorical(Participants) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 473 | 450 | 246 | 1169 |
| >=65 years | 98 | 123 | 41 | 262 |
| Age, Continuous(years) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| Mean | 53.1 ± 12.2 | 54.0 ± 11.9 | 51.6 ± 12.3 | 53.2 ± 12.1 |
| Sex: Female, Male(Participants) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| Female | 359 | 328 | 184 | 871 |
| Male | 212 | 245 | 103 | 560 |
| Race (NIH/OMB)(Participants) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 569 | 573 | 286 | 1428 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Body Mass Index (BMI)(kg/m^2) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| Mean | 28.36 ± 5.14 | 28.67 ± 5.87 | 28.46 ± 5.21 | 28.50 ± 5.46 |
| Duration of asthma disease(years) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| Mean | 24.8 ± 12.2 | 26.2 ± 12.6 | 24.5 ± 12.4 | 25.3 ± 12.4 |
| Duration of asthma disease by group(Participants) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| < 5 years | 26 | 21 | 13 | 60 |
| 5-20 years | 180 | 165 | 96 | 441 |
| ≥ 20 years | 365 | 387 | 178 | 930 |
| Number of asthma exacerbations in the previous year(asthma exacerbations) | CHF 5993 | CHF 1535 | CHF 1535 + Tiotropium (Tio) | Total |
|---|---|---|---|---|
| Mean | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.4 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 244 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical researchers, conducting legitimate research, patient-level data, study-level data, the clinical protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared patient-level data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Time frame: See information above in Plan Description regarding Chiesi's commitment to share information with qualified scientific and medical researchers, conducting legitimate research Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Data sharing details ↗ · www.chiesi.com
Ran from Apr 2016 to primary completion in May 2018, 25 months.
Results were first posted in May 2026, 8 years after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.